Inspection Record

Avexis — FDA 483 Findings

US FDAInspected 2019-08-02Published 2019-08-08 5 findingsLaboratory and QC controlsQuality unit oversightDeviation, CAPA, and investigation

Inspectors Scott T Ballard · Mihaly S LigmondThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Laboratory records do not include complete records of any testing and standardization of laboratory reference standards.

2Laboratory and QC controls

Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.

3Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not fully followed.

4Laboratory and QC controls

Established test procedures are not followed.

5Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

About this record

Extracted automatically from the document US FDA published on 2019-08-08. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Avexis company profile — full history US FDA documents, 2019 Go to Findings search